Safety advisory · HFP Constituent Updates

EPA and DHA Omega-3 Qualified Health Claims: FDA Safety Advisory (Sep 26, 2024)

Agency action: Sep 26, 2024Record ID: hfp_constitu-4f469558a202f5d5
View official source ↗

What happened

Original notice title

FDA Announces New Qualified Health Claims for EPA and DHA Omega-3 Consumption and the Risk of Hypertension and Coronary Heart Disease

From the archived source record

The U.S. Food and Drug Administration announced today that it does not intend to object to the use of certain qualified health claims stating that consuming eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) omega-3 fatty acids in food or dietary supplements may reduce the risk of hypertension and coronary heart disease. Specifically, the FDA responded to a health claim petition submitted by The Global Organization for EPA and DHA Omega-3s in a letter of enforcement discretion. Enforcement discretion means that FDA does not intend to object to the claim if it is used consistent with the factors described in the letter of enforcement discretion . The FDA determined that the overall evidence did not meet the “significant scientific agreement” standard required for an authorized health claim but did meet the “credible evidence” standard for a qualified health claim in the labeling of conventional foods and dietary supplements. The agency found that while there is some credible evidence suggesting that combined intake of EPA and DHA from conventional foods and dietary supplements may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent. EPA and DHA omega-3 fatty acids are found primarily in some fatty fish, fish oils and dietary supplements. Under FDA’s health claim regulations, foods and dietary supplements that bear a health claim must meet requirements regarding levels of certain nutrients. These requirements and the enforcement discretion factors FDA intends to consider for the use of this qualified health claim are described in detail in the letter of enforcement discretion issued to the petitioner. One of these enforcement discretion factors is that dietary supplements and conventional foods labeled with the qualified health claim contain at least 0.8 g EPA and DHA (combined total) per serving. To prevent consumer deception about the strength of the science underlying the new claim, the qualified health claim must be accompanied by a disclaimer or other qualifying language that accurately describes the level of scientific evidence supporting the claim. The FDA intends to exercise enforcement discr

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Published FDA communication
Source checked
Jul 16, 2026
Record revision
4ad4fec4a5a7

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
FDA Announces New Qualified Health Claims for EPA and DHA Omega-3 Consumption and the Risk of Hypertension and Coronary Heart Disease
Company
Not specified
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.